Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement

被引:0
作者
Bor-Sheng Ko
Cheng-Shyong Chang
Ming-Chih Chang
Tsai Yun Chen
Tzeon-Jye Chiou
Chang-Fang Chiu
Wen-Li Huang
Woei-Yau Kao
Yii-Jenq Lan
Shen-Fung Lin
Tran-Der Tan
Jih-Luh Tang
Cheng-Hwai Tzeng
Po-Nan Wang
Su-Pen Yet
Hwei-Fang Tien
机构
[1] National Taiwan University Hospital,Division of Hematology, Department of Internal Medicine
[2] National Health Research Institute,Institute of Systemic and Cellular Medicine
[3] Changhua Christian Hospital,Department of Internal Medicine
[4] Mackay Memorial Hospital,Department of Hematology
[5] Mackay Medical College,Oncology
[6] College of Medicine,Section of Hematology/Oncology, Department of Internal Medicine
[7] National Cheng Kung University,Division of Transfusion Medicine, Department of Medicine
[8] Taipei Veterans General Hospital,Cancer Center
[9] National Yang-Ming University School of Medicine,Department of Medicine
[10] China Medical University Hospital,Division of Hematology/Oncology
[11] School of Medicine,Division of Hematology
[12] China Medical University,Oncology, Department of Internal Medicine
[13] Taichung Veterans General Hospital,Division of Hematology
[14] Buddhist Tzu-Chi General Hospital Taipei Branch,Oncology, Department of Internal Medicine
[15] Chang Gung Memorial Hospital-Keelung,Division of Hematology
[16] Kaohsiung Medical University,Oncology, Department of Internal Medicine
[17] College of Medicine,Department of Internal Medicine
[18] Kaohsiung Medical University,Hematology and Medical Oncology
[19] Koo Foundation Sun Yat-Sen Cancer Center,Division of Hematology/Oncology, Department of Medicine
[20] Taipei Veterans General Hospital,Division of Hematology
[21] National Yang-Ming University School of Medicine,Oncology, Department of Internal Medicine
[22] Chang Gung Memorial Hospital-Linkou,undefined
来源
International Journal of Hematology | 2014年 / 100卷
关键词
Guidelines; Taiwan; MDS; ICT; Iron overload; Ferritin;
D O I
暂无
中图分类号
学科分类号
摘要
Iron overload is common in myelodysplastic syndrome (MDS) patients, and an accumulation of evidence shows that iron chelation may have benefits in these patients. However, discussion and consensus about iron chelation therapy (ICT) for MDS patients is lacking in Taiwan and other Southeast Asian countries. An Expert Panel in Taiwan was organized in 2011 to develop iron overload guidelines and provide a uniform reference for physicians treating MDS patients with iron overload, with specific regard to when to initiate ICT, in which patients, and the clinical and scientific rationale behind its use.
引用
收藏
页码:7 / 15
页数:8
相关论文
共 50 条
  • [21] Iron overload-induced oxidative stress in myelodysplastic syndromes and its cellular sequelae
    Kim, Cecilia H.
    Leitch, Heather A.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 163
  • [22] Impact of HFE gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes
    Schneeweiss-Gleixner, Mathias
    Greiner, Georg
    Herndlhofer, Susanne
    Schellnegger, Julia
    Krauth, Maria-Theresa
    Gleixner, Karoline, V
    Wimazal, Friedrich
    Steinhauser, Corinna
    Kundi, Michael
    Thalhammer, Renate
    Schwarzinger, Ilse
    Hoermann, Gregor
    Esterbauer, Harald
    Fodinger, Manuela
    Valent, Peter
    Sperr, Wolfgang R.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (03): : 955 - +
  • [23] Impact of HFE gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes
    Schneeweiss-Gleixner, Mathias
    Greiner, Georg
    Herndlhofer, Susanne
    Schellnegger, Julia
    Krauth, Maria-Theresa
    Gleixner, Karoline, V
    Wimazal, Friedrich
    Steinhauser, Corinna
    Kundi, Michael
    Thalhammer, Renate
    Schwarzinger, Ilse
    Hoermann, Gregor
    Esterbauer, Harald
    Foedinger, Manuela
    Valent, Peter
    Sperr, Wolfgang R.
    COGENT SOCIAL SCIENCES, 2021, 7 (01): : 955 - +
  • [24] Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome
    Zeidan, Amer M.
    Pullarkat, Vinod A.
    Komrokji, Rami S.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 117 : 57 - 66
  • [25] Managing Iron Overload in Patients with Myelodysplastic Syndromes with Oral Deferasirox Therapy
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Taher, Ali
    Kantarjian, Hagop M.
    ONCOLOGIST, 2009, 14 (05) : 489 - 496
  • [26] Study of deferoxamine in subcutaneous profusion treatment of iron overload in myelodysplastic syndromes
    González, FA
    Arrizabalaga, B
    Villegas, A
    Alonso, D
    Castro, M
    Remacha, A
    del Arco, A
    Núñez, GM
    MEDICINA CLINICA, 2005, 124 (17): : 645 - 647
  • [27] Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy
    Shammo, Jamile M.
    Komrokji, Rami S.
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (07) : 577 - 586
  • [28] Pharmacoeconomic Considerations in Treating Iron Overload in Patients with β-Thalassaemia, Sickle Cell Disease and Myelodysplastic Syndromes in the USA Literature Review
    Bin Zhang
    Prina Z. Donga
    Mitra Corral
    Medha Sasane
    Jeffrey D. Miller
    Chris L. Pashos
    PharmacoEconomics, 2011, 29 : 461 - 474
  • [29] Impact of iron overload by transfusion on survival and leukemia transformation of myelodysplastic syndromes in a single center of China
    Wang, Yihao
    Huang, Lei
    Hua, Yanni
    Liu, Hui
    Jiang, Huijuan
    Wang, Huaquan
    Zhang, Wei
    Fu, Rong
    Shao, Zonghong
    HEMATOLOGY, 2021, 26 (01) : 874 - 880
  • [30] Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements
    Remacha, Angel F.
    Arrizabalaga, Beatriz
    Del Canizo, Consuelo
    Sanz, Guillermo
    Villegas, Ana
    ANNALS OF HEMATOLOGY, 2010, 89 (02) : 147 - 154